IL-17 interleukins & resistance to EGFR therapies
The group led by Jerome Giustiniani and Armand Bensussan (INSERM/Institut Godinot/OREGA Biotech) reported that IL-17B and IL-17E may promote triple negative breast cancer (TNBC) resistance to EGFR inhibitors. Their work suggests that inhibiting these cytokines may improve the response to EGFR inhibitor and the management of these cancers. (Read the article)
Furthermore, they also reviewed the role of IL-17 interleukins in cancer: Read the review.